BioStock: Elicera gets green light for CAR T clinical study

Elicera Therapeutics has gotten the approval to begin a phase I/IIa study with lead CAR T candidate ELC-301 in B cell lymphoma, mantle cell lymphoma or indolent lymphoma. This is a key milesone for the Swedish biotech, who is banking on its iTANK technology platform to enhance a patient’s immune system in the face of cancer. BioStock spoke with Elicera’s CEO Jamal El-Mosleh to learn more.

Read the interview with Jamal El-Mosleh at biostock.se:

Elicera gets green light for CAR T clinical study - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/